Article Information
History
- July 3, 2024.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Albertus Ari Adrianto1,*,
- Ignatius Riwanto1,
- Udadi Sadhana2,
- Dewi Kartikawati Paramita3,4,5,
- Henry Setyawan6,
- Kevin Christian Tjandra7,*,
- Danendra Rakha Putra Respati7,
- Derren David Christian Homenta Rampengan8,
- Roy Novri Ramadhan9,
- Gastin Gabriel Jangkang10 and
- Endang Mahati11
- 1Department of Digestive Surgery, Faculty of Medicine, Universitas Diponegoro, Semarang, Indonesia
- 2Department of Anatomical Pathology, Faculty of Medicine, Universitas Diopnegoro, Semarang, Indonesia
- 3Department of Histology and Cell Biology, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia
- 4Integrated Research Laboratory, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia;
- 5Study Center for Biotechnology, Universitas Gadjah Mada, Yogyakarta, Indonesia
- 6Department of Public Health, Faculty of Public Health, Universitas Diponegoro, Semarang, Indonesia;
- 7Department of Medicine, Faculty of Medicine, Universitas Diponegoro, Semarang, Indonesia
- 8Medical Program, Faculty of Medicine, Universitas Sam Ratulangi
- 9Medical Program, Faculty of Medicine, Universitas Airlangga
- 10Medical Program, Faculty of Medicine, Universitas Lambung Mangkurat
- 11Department of Pharmacology and Therapeutic, Faculty of Medicine, Diponegoro University, Semarang, Indonesia
- ↵*Correspondence: Albertus Ari Adrianto, Jl. Prof. Sudarto, Tembalang, Kec. Tembalang, Kota Semarang, Jawa Tengah 50275, Tel +628122824838, Fax - Email: medpubdiponegoro{at}gmail.com, email: kevinchristian2841{at}gmail.com
Posted July 03, 2024.
The Efficacy and Safety of Pembrolizumab, Ipilimumab, and Nivolumab Monoteraphy and Combination for Colorectal Cancer: A Systematic Review and Meta-Analysis
